<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00109005</url>
  </required_header>
  <id_info>
    <org_study_id>050095</org_study_id>
    <secondary_id>05-C-0095</secondary_id>
    <nct_id>NCT00109005</nct_id>
    <nct_alias>NCT00112606</nct_alias>
  </id_info>
  <brief_title>Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma</brief_title>
  <official_title>A Randomized Phase II Study of Oral Lenalidomide (Revlimid [TM]), an Antiangiogenic and Immunomodulatory Agent, in Subjects With Stage IV Ocular Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test whether an experimental drug called Revlimid (lenalidomide) can reduce
      tumor size and prolong survival in patients with metastatic melanoma (melanoma that has
      spread beyond the original tumor site). It will also examine the toxicity and blood effects
      of Revlimid.

      Patients 18 years of age and older with stage IV ocular melanoma may be eligible for this
      study. Candidates are screened with a medical history and physical and examination, blood and
      urine tests, electrocardiogram, chest x-ray, computed tomography (CT) scan and other imaging
      scans if needed, such as a bone scan, magnetic resonance imaging (MRI), ultrasound, or
      positron emission tomography (PET).

      Participants are admitted to the National Institutes of Health (NIH) Clinical Center for 24
      hours for their first oral dose of Revlimid. During the hospital stay, blood is drawn before
      the dose is given and again at 0.25, 0.5, 1, 2, 4, 6, 9, 12 and 24 hours after dosing to see
      how the body handles the drug. If the drug is well tolerated, patients are sent home with a
      21-day supply of drug to take once a day for 21 days, then go off drug 7 days. This regimen
      constitutes one 28-day treatment cycle. Treatment cycles may continue for up to 2 years.

      Patients keep a daily diary of side effects and have blood drawn once a week. The drug dose
      may be adjusted according to the laboratory test results. If unacceptable toxicity occurs,
      treatment may be stopped.

      Patients who agree to be biopsied undergo this procedure before treatment begins and at the
      end of treatment cycles 3 and 6. A small area of skin is numbed with medicine and a small
      piece of tumor is removed with a needle or by a small cut in the tumor. The tissue is
      examined under a microscope.

      Patients return to NIH after the first month of treatment and then every 3 months to evaluate
      their tumors and treatment of side effects. The visits include a physical examination, x-rays
      and scans to evaluate tumors. Visits are scheduled every 3 months while on treatment; then
      every 3 months for 2 years afterwards; then every 4 months for 1 year; and as needed after
      that. Patients will have a brain magnetic resonance imaging scan once a year to watch for new
      tumor areas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

        -  Patients with stage IV ocular melanoma have very few available treatment options and an
           overall poor prognosis.

        -  Pre-clinical and early clinical evidence suggest that lenalidomide has activity against
           solid tumors.

        -  This trial is designed to evaluate the safety and efficacy of two different doses of a
           novel antiangiogenic and immunomodulatory agent, lenalidomide (Revlimid ).

      Objectives:

      Primary Objectives:

        -  Determine the response rate to lenalidomide at two dose levels for patients with Stage
           IV ocular melanoma.

        -  To determine the toxicity of lenalidomide at two dose levels in this setting.

      Secondary Objectives:

        -  To determine the progression free and overall survival of patients with Stage IV ocular
           melanoma treated with lenalidomide.

        -  When easily accessible, obtain tissue at baseline and during therapy to evaluate the
           effects of these agents on pathways, thought to be modulated by lenalidomide in
           pre-clinical studies.

        -  To determine the pharmacokinetics of lenalidomide at these two doses in patients with
           Stage IV ocular melanoma.

        -  To determine if there is a dose level with potentially superior efficacy and acceptable
           toxicity.

      Eligibility:

        -  Patients &gt; 18 years of age with stage IV ocular melanoma, who have measurable disease.

        -  Patient must be Eastern Cooperative Oncology Group (ECOG) performance status of = 2 and
           a life expectancy of more than 3 months.

        -  Patients must have adequate organ function.

        -  Patients must not have had prior surgery, chemotherapy, hormonal therapy, radiation
           therapy, or biological therapy for at least 4 weeks prior to starting study medication.

        -  Patients who were receiving mitomycin C, nitrosoureas, or carboplatin must be 6 weeks
           from the last administration of chemotherapy.

        -  Patients must not have an acute, critical illness,.

        -  All patients who are sexually active and able to conceive will be required to use
           contraception during treatment with lenalidomide

      Design:

        -  A phase II trial in which patients are randomized to 2 dose levels of lenalidomide
           administered for 21 days every 28 days for 2 years.

        -  76 patients (allowing for up to 3 inevaluable patients per dose level) will be enrolled
           over 4 to 5 years.

        -  The objective of the trial will be to determine in each of the two groups of patients (5
           mg and 25 mg dose levels) whether, CC5013 is able to be associated with a response rate
           (partial response (PR) + complete response (CR)) that can rule out 10% (p0=0.10) in
           favor of an improved response rate of 30% (p1=0.30).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Responses in Patients With Metastatic Ocular Melanoma</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical response is assessed by the Response Evaluation Criteria for Adverse Events in Solid Tumors (RECIST). Complete response (CR) is disappearance of all target lesions. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions. Progressive disease (PD) is at least a 20% increase in the sum of the LD of target lesions. Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <description>Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Time interval from start of treatment to documented evidence of disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Date of on-study to the date of death from any cause or last follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine Pharmacokinetics of Lenalidomide at Two Dose Levels: 5 mg and 25 mg</measure>
    <time_frame>Prior to treatment on cycle 1, day 1 and then on cycle 1, day 1 at 0.25, 0.5, 1, 2, 4, 6, 9 and 12 hours. Cycle 1, day 2 at 24 hours.</time_frame>
    <description>Plasma samples will be obtained and plasma concentrations will be determined by a reversed-phase high-performance liquid chromatography (HPLC) assay using mass spectrometry (MS) detection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine Dose Level With Superior Efficacy and Acceptable Toxicity</measure>
    <time_frame>up to 2 years</time_frame>
    <description>The most efficacious dose (with greater number of responses) with acceptable toxicity profile will be considered for use in subsequent trials. iI the number of responses is tied, then toxicity criteria (Common Terminology criteria (CTC) v3.0) will be used to select the preferred dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Effects of Lenalidomide on Pathways</measure>
    <time_frame>Baseline and at the end of treatment cycles 3 and 6. Every 21 day supply of lenalidomide with a 7 day rest (total of 28 days) will be considered a cycle of therapy.</time_frame>
    <description>Tissue will be obtained to evaluate the effects of lenalidomide on pathways thought to be modulated by lenalidomide.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - 25 mg lenalidomide (Revlimid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral dose (1 capsule) lenalidomide 25 mg per day 7 days a week for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - 5 mg lenalidomide (Revlimid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral dose (1 capsule) lenalidomide 5 mg per day 7 days a week for 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Revlimid</intervention_name>
    <description>oral dose (1 capsule) 25 mg per day 7 days a week for cohort 1 oral dose (1 capsule) 5 mg per day 7 days a week for cohort 2</description>
    <arm_group_label>Cohort 1 - 25 mg lenalidomide (Revlimid)</arm_group_label>
    <arm_group_label>Cohort 2 - 5 mg lenalidomide (Revlimid)</arm_group_label>
    <other_name>Lenalidomide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -INCLUSION CRITERIA:

          1. All patients with stage IV ocular melanoma, who have measurable disease will be
             considered.

          2. Patients must have histopathological documentation of ocular melanoma confirmed in the
             Laboratory of Pathology/National Cancer Institute (NCI) of the Clinical Center at the
             National Institutes of Health. This can be from tissue obtained outside the National
             Institutes of Health (NIH).

          3. Patient must be Eastern Cooperative Oncology Group (ECOG) performance status of less
             than or equal to 2.

          4. Patients must have a life expectancy of more than 3 months.

          5. Hematological eligibility parameters (prescreen):

               -  Granulocyte count greater than 1,500/mm^3

               -  Platelet count greater than 100,000/mm^3

               -  If the creatinine is greater than 1.5 mg/dL, obtain a 24 hour urine collection.
                  Creatinine clearance must be greater than 60 mL/min/1.73m^2.

               -  Hepatic function: bilirubin (total) less than or equal to 2.0 mg/dl; Alanine
                  aminotransferase (ALT) less than 10 x upper limit of normal; Aspartate
                  aminotransferase (AST) less than 10 x upper limit of normal.

          6. Patients must have recovered from any acute toxicity related to prior therapy or
             surgery, to a grade 1 or less unless specified above.

          7. Patients must not have had prior surgery, chemotherapy, hormonal therapy, radiation
             therapy, or biological therapy, for at least 4 weeks prior to starting study
             medication. Patients who were receiving mitomycin C, nitrosoureas, or carboplatin must
             be 6 weeks from the last administration of chemotherapy.

          8. Patients must not have an acute, critical illness, including a serious untreated
             infection.

          9. Patients must be willing to return to the National Institutes of Health (NIH) for
             follow-up visits.

         10. All patients who are sexually active and able to conceive will be required to use
             contraception during treatment with lenalidomide.

        Only two criteria are allowed by the Food and Drug Administration (FDA) for the status of
        not of child bearing potential: hysterectomy or menopause for 24 consecutive months. Women
        of child bearing potential will be required to use two methods of birth control, one highly
        effective method and one additional method, at the same time during treatment and for one
        month after the completion of lenalidomide treatment. These methods must be used for at
        least four weeks before starting lenalidomide, during treatment, and for at least four
        weeks following the last dose of lenalidomide. Acceptable forms of birth control include:

        Intrauterine device (IUD)

        Latex condom

        Hormonal (Birth control pills, injections, implants)

        Diaphragm

        Tubal Ligation

        Cervical cap

        Partner's vasectomy

        Two barrier methods may be used if the physician agrees that the highly effective methods
        are medically contraindicated.

        Women of childbearing potential must have a negative urine pregnancy test 24 hours prior to
        the start of lenalidomide.

        Men who are sexually active must agree to use latex condoms.

        Patients must be able to understand and sign informed consent form.

        Patients must be greater than or equal to 18 years of age.

        EXCLUSION CRITERIA:

          1. Patients with evidence of active brain metastases will be excluded. Patients must have
             had a complete excision or radiotherapy and remain asymptomatic with stable disease as
             shown by magnetic resonance imaging (MRI) for at least six months.

          2. Patients who are pregnant or lactating. No data is currently available about the
             excretion of lenalidomide in breast milk. Although no preclinical data suggest
             teratogenicity with this compound, because of the relationship to thalidomide, we will
             exclude patients who are pregnant or lactating.

          3. Patients with a history of unstable or newly diagnosed angina pectoris, recent
             myocardial infarction (within 6 months of enrollment), New York class II-IV congestive
             heart failure, chronic obstructive lung disease requiring oxygen therapy or
             uncontrolled seizure activity are not eligible.

          4. Patients who are known positive for human immunodeficiency virus (HIV) as it may
             increase their risk of infection since lenalidomide has effects on cells involved in
             the immune system.

          5. Patients who have had prior therapy with lenalidomide.

          6. Patients with known hypersensitivity reaction to lenalidomide.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caryn Steakley</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, National Institutes of Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Institute (NCI)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/detail/A_2005-C-0095.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Gragoudas ES, Egan KM, Seddon JM, Glynn RJ, Walsh SM, Finn SM, Munzenrider JE, Spar MD. Survival of patients with metastases from uveal melanoma. Ophthalmology. 1991 Mar;98(3):383-9; discussion 390.</citation>
    <PMID>2023760</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2005</study_first_submitted>
  <study_first_submitted_qc>April 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2005</study_first_posted>
  <results_first_submitted>August 29, 2012</results_first_submitted>
  <results_first_submitted_qc>September 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 30, 2012</results_first_posted>
  <last_update_submitted>November 14, 2016</last_update_submitted>
  <last_update_submitted_qc>November 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Caryn Steakley, R.N.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Response Rate</keyword>
  <keyword>Toxicity</keyword>
  <keyword>Progression-Free Survival</keyword>
  <keyword>Overall Survival</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Ocular Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1 - 25 mg Lenalidomide (Revlimid)</title>
          <description>oral dose (1 capsule) lenalidomide 25 mg per day 7 days a week for 3 weeks</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2 - 5 mg Lenalidomide (Revlimid)</title>
          <description>oral dose (1 capsule) lenalidomide 5 mg per day 7 days a week for 3 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1 - 25 mg Lenalidomide (Revlimid)</title>
          <description>oral dose (1 capsule) lenalidomide 25 mg per day 7 days a week for 3 weeks</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2 - 5 mg Lenalidomide (Revlimid)</title>
          <description>oral dose (1 capsule) lenalidomide 5 mg per day 7 days a week for 3 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.7" spread="7.6"/>
                    <measurement group_id="B2" value="58.86" spread="9.83"/>
                    <measurement group_id="B3" value="55.56" spread="9.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Responses in Patients With Metastatic Ocular Melanoma</title>
        <description>Clinical response is assessed by the Response Evaluation Criteria for Adverse Events in Solid Tumors (RECIST). Complete response (CR) is disappearance of all target lesions. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions. Progressive disease (PD) is at least a 20% increase in the sum of the LD of target lesions. Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.</description>
        <time_frame>12 months</time_frame>
        <population>Response data was combined for this outcome measure. Results are available for the combined cohorts only.
Sixteen out of seventeen patients were eligible for response assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 &amp; 2 -25 mg &amp; 5 mg Lenalidomide (Revlimid)</title>
            <description>oral dose (1 capsule) lenalidomide 25 mg per day 7 days a week for 3 weeks oral dose (1 capsule) lenalidomide 5 mg per day 7 days a week for 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Responses in Patients With Metastatic Ocular Melanoma</title>
          <description>Clinical response is assessed by the Response Evaluation Criteria for Adverse Events in Solid Tumors (RECIST). Complete response (CR) is disappearance of all target lesions. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions. Progressive disease (PD) is at least a 20% increase in the sum of the LD of target lesions. Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.</description>
          <population>Response data was combined for this outcome measure. Results are available for the combined cohorts only.
Sixteen out of seventeen patients were eligible for response assessments.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - 25 mg Lenalidomide (Revlimid)</title>
            <description>oral dose (1 capsule) lenalidomide 25 mg per day 7 days a week for 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2 - 5 mg Lenalidomide (Revlimid)</title>
            <description>oral dose (1 capsule) lenalidomide 5 mg per day 7 days a week for 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Time interval from start of treatment to documented evidence of disease progression.</description>
        <time_frame>up to 2 years</time_frame>
        <population>This outcome measure was not analyzed because the investigator left the institution.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 &amp; 2 -25 mg &amp; 5 mg Lenalidomide (Revlimid)</title>
            <description>oral dose (1 capsule) lenalidomide 25 mg per day 7 days a week for 3 weeks oral dose (1 capsule) lenalidomide 5 mg per day 7 days a week for 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Time interval from start of treatment to documented evidence of disease progression.</description>
          <population>This outcome measure was not analyzed because the investigator left the institution.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Date of on-study to the date of death from any cause or last follow up.</description>
        <time_frame>up to 2 years</time_frame>
        <population>This outcome measure was not analyzed because the investigator left the institution.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 &amp; 2 -25 mg &amp; 5 mg Lenalidomide (Revlimid)</title>
            <description>oral dose (1 capsule) lenalidomide 25 mg per day 7 days a week for 3 weeks oral dose (1 capsule) lenalidomide 5 mg per day 7 days a week for 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Date of on-study to the date of death from any cause or last follow up.</description>
          <population>This outcome measure was not analyzed because the investigator left the institution.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine Pharmacokinetics of Lenalidomide at Two Dose Levels: 5 mg and 25 mg</title>
        <description>Plasma samples will be obtained and plasma concentrations will be determined by a reversed-phase high-performance liquid chromatography (HPLC) assay using mass spectrometry (MS) detection.</description>
        <time_frame>Prior to treatment on cycle 1, day 1 and then on cycle 1, day 1 at 0.25, 0.5, 1, 2, 4, 6, 9 and 12 hours. Cycle 1, day 2 at 24 hours.</time_frame>
        <population>This outcome measure was not analyzed because the investigator left the institution.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 &amp; 2 -25 mg &amp; 5 mg Lenalidomide (Revlimid)</title>
            <description>oral dose (1 capsule) lenalidomide 25 mg per day 7 days a week for 3 weeks oral dose (1 capsule) lenalidomide 5 mg per day 7 days a week for 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Determine Pharmacokinetics of Lenalidomide at Two Dose Levels: 5 mg and 25 mg</title>
          <description>Plasma samples will be obtained and plasma concentrations will be determined by a reversed-phase high-performance liquid chromatography (HPLC) assay using mass spectrometry (MS) detection.</description>
          <population>This outcome measure was not analyzed because the investigator left the institution.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine Dose Level With Superior Efficacy and Acceptable Toxicity</title>
        <description>The most efficacious dose (with greater number of responses) with acceptable toxicity profile will be considered for use in subsequent trials. iI the number of responses is tied, then toxicity criteria (Common Terminology criteria (CTC) v3.0) will be used to select the preferred dose.</description>
        <time_frame>up to 2 years</time_frame>
        <population>This outcome measure was not analyzed because the investigator left the institution.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 &amp; 2 -25 mg &amp; 5 mg Lenalidomide (Revlimid)</title>
            <description>oral dose (1 capsule) lenalidomide 25 mg per day 7 days a week for 3 weeks oral dose (1 capsule) lenalidomide 5 mg per day 7 days a week for 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Determine Dose Level With Superior Efficacy and Acceptable Toxicity</title>
          <description>The most efficacious dose (with greater number of responses) with acceptable toxicity profile will be considered for use in subsequent trials. iI the number of responses is tied, then toxicity criteria (Common Terminology criteria (CTC) v3.0) will be used to select the preferred dose.</description>
          <population>This outcome measure was not analyzed because the investigator left the institution.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate Effects of Lenalidomide on Pathways</title>
        <description>Tissue will be obtained to evaluate the effects of lenalidomide on pathways thought to be modulated by lenalidomide.</description>
        <time_frame>Baseline and at the end of treatment cycles 3 and 6. Every 21 day supply of lenalidomide with a 7 day rest (total of 28 days) will be considered a cycle of therapy.</time_frame>
        <population>This outcome measure was not analyzed because the investigator left the institution.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 &amp; 2 -25 mg &amp; 5 mg Lenalidomide (Revlimid)</title>
            <description>oral dose (1 capsule) lenalidomide 25 mg per day 7 days a week for 3 weeks oral dose (1 capsule) lenalidomide 5 mg per day 7 days a week for 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate Effects of Lenalidomide on Pathways</title>
          <description>Tissue will be obtained to evaluate the effects of lenalidomide on pathways thought to be modulated by lenalidomide.</description>
          <population>This outcome measure was not analyzed because the investigator left the institution.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1 - 25 mg Lenalidomide (Revlimid)</title>
          <description>oral dose (1 capsule) lenalidomide 25 mg per day 7 days a week for 3 weeks</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2 - 5 mg Lenalidomide (Revlimid)</title>
          <description>oral dose (1 capsule) lenalidomide 5 mg per day 7 days a week for 3 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCv3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death not associated with CTCAE term: Death Progression NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCv3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision-flashing lights/floaters</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain::Oral gums</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with unknown ANC::Lung (pneumonia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Skin (cellulitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC::(Sinus)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>INR (International Normalized Ratio of prothrombin time)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal/Soft tissue - Other (Specify, tingling of hands and R foot)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain::Muscle</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain: Back</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain: Extremity-limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain::Joint</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain::Head/headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Somnolence/depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Mood alteration::Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sweating (diaphoresis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Urticaria (hives, welts, wheals)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Caryn Steakley</name_or_title>
      <organization>National Cancer Institute, National Institutes of Health</organization>
      <phone>301-435-3685</phone>
      <email>steaklec@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

